Dr. Mamounas on Adjuvant Endocrine Therapy for Breast Cancer

Eleftherios (Terry) P. Mamounas, MD
Published: Thursday, Aug 31, 2017



Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.

For years, many thought that 5 years of tamoxifen was the standard, states Mamounas. Studies had shown that additional therapy to around 10 years did not show any improvement.

However, with 15 years of follow-up, there has been a benefit in disease-free survival in patients receiving 10 years of tamoxifen, explains Mamounas.



Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses adjuvant endocrine therapy for patients with breast cancer.

For years, many thought that 5 years of tamoxifen was the standard, states Mamounas. Studies had shown that additional therapy to around 10 years did not show any improvement.

However, with 15 years of follow-up, there has been a benefit in disease-free survival in patients receiving 10 years of tamoxifen, explains Mamounas.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x